Frontiers in Oncology Seminars
Rationale Combinatorial Approaches with Immune Checkpoint Blockade for the Treatment of Cancer
Stephen Hodi, MD
May 4, 2021
Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute, and Professor of Medicine at Harvard Medical School.
Dr. Hodi’s research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. In particular, Dr. Hodi is known for the clinical development of immune checkpoint inhibitors. His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer.